Last reviewed · How we verify
Filgrastim (G-CSF)
Filgrastim is a granulocyte-colony stimulating factor (G-CSF) that stimulates the bone marrow to produce and release neutrophils into the bloodstream.
Filgrastim is a granulocyte-colony stimulating factor (G-CSF) that stimulates the bone marrow to produce and release neutrophils into the bloodstream. Used for Chemotherapy-induced neutropenia, Severe chronic neutropenia, Mobilization of peripheral blood progenitor cells for stem cell transplantation.
At a glance
| Generic name | Filgrastim (G-CSF) |
|---|---|
| Also known as | Neupogen, Granul, Neupogen®, G-CSF, G-CSF, neupogen |
| Sponsor | University of Miami |
| Drug class | Granulocyte-colony stimulating factor (G-CSF) |
| Target | G-CSF receptor (GCSFR) |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology, Hematology |
| Phase | Phase 3 |
Mechanism of action
Filgrastim binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their proliferation, differentiation, and activation. This increases circulating neutrophil counts, enhancing immune function and reducing infection risk in patients with neutropenia or undergoing chemotherapy.
Approved indications
- Chemotherapy-induced neutropenia
- Severe chronic neutropenia
- Mobilization of peripheral blood progenitor cells for stem cell transplantation
- Post-myeloid reconstitution following bone marrow transplantation
Common side effects
- Bone pain
- Headache
- Fatigue
- Fever
- Splenic rupture (rare)
- Acute respiratory distress syndrome (rare)
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Improving White Blood Cell Collection From Healthy Donors (PHASE4)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (PHASE1)
- Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Filgrastim (G-CSF) CI brief — competitive landscape report
- Filgrastim (G-CSF) updates RSS · CI watch RSS
- University of Miami portfolio CI